



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Daliresp (roflumilast) Page: 1 of 1

Effective Date: 4/1/2024 Last Review Date: 3/2024

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Texas

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Daliresp (roflumilast) under the patient's prescription drug benefit.

### Description:

Daliresp (roflumilast) is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

#### Limitations of Use

Daliresp (roflumilast) is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

Daliresp (roflumilast) 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.

### Applicable Drug List:

Roflumilast

### Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in a patient with severe COPD associated with chronic bronchitis and a history of exacerbations

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months

### References:

1. Daliresp [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2019.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed August 8, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/08/2023).